Joshua Jackson, MD, PhD

Joshua Jackson


University of Alabama at Birmingham, MD, 2019
University of Alabama at Birmingham, PhD, Cancer Biology, 2015
Auburn University, MChE, Chemical Engineering, 2010
Tennessee Technological University, BS, Chemical Engineering, 2008

Research Interests

Brain tumor biology and immunology, surgical device engineering


Guitars, record collecting, film photography and film chemistry, reading, history, skiing, hiking, and caving


Ghonime, M.G., Jackson, J., Shah, A., Roth, J., Li, M., Saunders, U., Coleman, J., Gillespie, G.Y., Markert, J.M. and Cassady, K.A., Chimeric HCMV/HSV-1 and Δγ134. 5 oncolytic herpes simplex virus elicit immune mediated anti-gliomal effect and anti-tumor memory. Translational Oncology, 2018, 11(1), pp.86-93.
Jackson, J.D., Markert, J.M., Li, L., Carroll, S.L. and Cassady, K.A., STAT1 and NF-κB inhibitors diminish basal interferon-stimulated gene expression and improve the productive infection of oncolytic HSV in MPNST cells. Molecular Cancer Research, 2016, 14(5), pp.482-492.
Cassady KA, Haworth KB, Jackson JD, Markert JM, Cripe TP. To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses. 2016, 8(2):43.
Jackson, J.D., McMorris, A.M., Roth, J.C., Coleman, J.M., Whitley, R.J., Gillespie, G.Y., Carroll, S.L., Markert, J.M. and Cassady, K.A., Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Therapy, 2014, 21(11), p.984.
Jackson, J.D., Weis, D.C. and Visco Jr, D.P., Potential Glucocorticoid Receptor Ligands with Pulmonary Selectivity Using I‐QSAR with the Signature Molecular Descriptor. Chemical Biology & Drug Design, 2008, 72(6), pp.540-550.